Facial Soft-Tissue Fillers: Assessing the State of the Science conference---Proceedings report

Hanke, C. William; Rohrich, Rodney J; Busso, Mariano; Carruthers, Alastair; Carruthers, Jean; Fagien, Steven; Fitzgerald, Rebecca; Glogau, Richard G.; Greenberger, Phyllis; Lorenc, Z. Paul; Marmur, Ellen S.; Monheit, Gary D.; Pusic, Andrea L.; Rubin, Mark G.; Rzany, Berthold; Sclafani, Anthony P.; Taylor, Susan C.; Weinkle, Susan; McGuire, Michael F.; Pariser, David M.; Casas, Laurie A.; Collishaw, Karen J.; Dailey, Roger A.; Duffy, Stephen C.; Edgar, Elizabeth Jan; Greenan, Barbara L.; Haenlein, Kelly; Henrichs, Ronald A.; Hume, Keith M.; Lum, Flora; Nielsen, David R.; Poulsen, Lisle; Shoaf, Lori; Seward, William Henry; Begolka, Wendy Smith; Stanton, Robert G.; Svedman, Katherine J.; Thomas, J. Regan; Sykes, Jonathan M.; Wargo, Carol; Weiß, Robert

doi:10.1016/j.jaad.2011.02.008

Cited by 11 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 It was first isolated in 1934 from bovine vitreous humor. [11][12][13] HA is a polysaccharide composed of repeating units of D-glucuronic acid and N-acetyl-glucosamine. It is found in all tissues of vertebrates and is very prevalent in human skin.…”

Section: Introductionmentioning

confidence: 99%

A new dermal filler made of cross‐linked and auto‐cross‐linked hyaluronic acid in the correction of facial aging defects

Sparavigna

Fino

Tenconi

et al. 2014

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A new dermal filler made of cross‐linked and auto‐cross‐linked hyaluronic acid in the correction of facial aging defects

Sparavigna

Fino

Tenconi

et al. 2014

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Recently, the outcomes of a large conference on facial soft tissue fillers in the USA were published [66][67][68][69]. The conference was a joint effort of seven American professional societies, spanning the variety of clinicians applying these products.…”

Section: Us Soft-tissue Fillers Conferencementioning

confidence: 99%

Clinical data on injectable tissue fillers: a review

Vries

Geertsma

2013

Expert Review of Medical Devices

View full text Add to dashboard Cite

Treatment with injectable tissue fillers for aesthetic purposes is increasingly popular. In parallel with this success, questions related to the safety of these treatments and the products involved are being raised more prominently. To gain insight in the safety aspects of injectable tissue fillers, we performed a literature review to collect studies reporting clinical data of injectable tissue fillers. We found several case reports where serious complications after more than three years are described. However, there are only a limited number of well-defined prospective clinical studies available with follow-up periods longer than three years. Furthermore, causes of complications, that is, treatment or product related, are often not specified in literature. Considering the intended functional period of fillers in combination with the known occurrence of long-term complications, there is a need for well-defined prospective clinical studies. In order to be able to discriminate between product failure (a product safety issue) or application methodology (a physician expertise or training issue), better identification of observed complications and whether they are product or treatment related, is needed. For the safe use of the fillers it is important that treatment with injectable tissue fillers is performed by a trained physician, who knows the product specifications and its applications. . Moreover, it is expected that due to increase in life expectancy, the demand for anti-aging treatments, like tissue augmentation with injectable tissue fillers, will grow [2]. Their success has been attributed to the fact that treatments with injectable tissue fillers are fast and appear to be relatively easy [2]. Only a relatively 'simple' subcutaneous injection is needed. Today, various injectable tissue fillers with different characteristics are available, for example, duration of the effect, material type and intended anatomical location.Although the application of an injectable tissue filler seems to be relatively simple and safe, reports of serious adverse effects have appeared in the literature [2][3][4][5][6][7][8]. Estimates of the occurrence of severe complications after treatment with various types of injectable tissue fillers range between 1:80 and 1:50,000 patients [9,10]. Adverse side effects can be caused by incorrect injection techniques (treatment related) or by the characteristics of the products (product related) [11,12]. Short-, mid-and long-term complications can be discerned (TABLE 1) [2,13-15]. Short-term complications like pain, swelling, fever, immediate hypersensitivity reactions, occur immediately or within several days past treatment and disappear after several weeks. A more severe short-term complication is necrosis [5,16]. Necrosis occurs immediately or within a few days if blood vessels are obstructed by the filler material or if they are injured during the treatment [17]. Mid-term complications such as delayed inflammatory reactions, ulceration and granuloma reaction may occur after 2-12 months. I...

show abstract

“…Hyaluronic acid (HA) is the most commonly used dermal filler worldwide for alleviating age‐related changes, such as wrinkles and volume loss, because of its safety and effectiveness 1‐3 . HA occurs naturally as a linear polysaccharide, with an in vivo half‐life shorter than 2 days 4 .…”

Section: Introductionmentioning

confidence: 99%

A multicenter, randomized, double‐blind comparison of two hyaluronic acid fillers in mid‐face volume restoration in Asians: A 2‐year extension study

Jung

Lee²,

Yoon

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

The long-term effectiveness and safety of hyaluronic acid fillers in mid-face volume restoration in Asians remain unclear. The objective of this study was to compare the longterm effectiveness and safety of Neuramis Volume Lidocaine (SHAPE-NVL) and Juvederm Voluma with Lidocaine (VYC-20L) in mid-face volume restoration in Asians. Overall, 88 Korean subjects with moderate-to-severe age-related mid-face volume deficit on the Mid-Face Volume Deficit Scale (MFVDS) received SHAPE-NVL on one side and VYC-20L on the contralateral side of the face. Of the 81 subjects who completed the 48-week primary study, 69 subjects were enrolled in an extension study lasting 104 weeks. MFVDS score and global aesthetic improvement were assessed at each visit. Response was defined as a ≥1-point reduction in MFVDS. At weeks 36 and 48, the responder rates for SHAPE-NVL were 81.93% and 80.72%, while those for VYC-20L were 85.54% and 81.92%, respectively. At the 104-week visit, the responder rates were 73.91% and 72.46% for SHAPE-NVL and VYC-20L, respectively. No subjects experienced any serious adverse events during the trial. SHAPE-NVL and VYC-20L showed comparable longevity and safety in mid-face volume restoration over 2 years in Asians. Both had durable effects for up to 2 years with minimal safety concerns.

show abstract

Facial Soft-Tissue Fillers: Assessing the State of the Science conference---Proceedings report

Cited by 11 publications

References 5 publications

A new dermal filler made of cross‐linked and auto‐cross‐linked hyaluronic acid in the correction of facial aging defects

A new dermal filler made of cross‐linked and auto‐cross‐linked hyaluronic acid in the correction of facial aging defects

Clinical data on injectable tissue fillers: a review

A multicenter, randomized, double‐blind comparison of two hyaluronic acid fillers in mid‐face volume restoration in Asians: A 2‐year extension study

Contact Info

Product

Resources

About